Y-shape Branched Pegylated Filgrastim clinical trials
How each study uses Y-shape Branched Pegylated Filgrastim is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses Y-shape Branched Pegylated Filgrastim is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving ChemotherapyCompletedPhase 3Xiamen Amoytop Biotech Co., Ltd.NCT04466137Written as YPEG-rhG-CSFHow we know
- Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving ChemotherapyCompletedPhase 2Xiamen Amoytop Biotech Co., Ltd.NCT02005458Written as YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycleHow we know
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy PatientsCompletedPhase 1Xiamen Amoytop Biotech Co., Ltd.NCT01238562Written as YPEG-FilgrastimHow we know